Skip to main content

Advertisement

Novel mutation of the LPIN2 gene in Turkish brothers with Majeed syndrome. Response to IL-1 inhibition

Article metrics

  • 1170 Accesses

  • 2 Citations

Background

Majeed syndrome is a rare, syndromic form of chronic recurrent multifocal osteomyelitis (CRMO) first described in 1989. The syndrome starts during infancy with recurrent relapses of osteomyelitis typically associated with fever, congenital dyserythropoietic anemia (CDA) and often neutrophilic dermatosis (Sweet syndrome). Homozygous mutations in the LPIN2 gene located on the short arm of chromosome 18 have been identified as being responsible for the Majeed syndrome.

Aim

To report a novel mutation in the LPIN2 gene detected in two brothers with Majeed syndrome and to describe the clinical characteristics and response to treatment.

Case presentations

Two Turkish brothers (13 (Y) and 29 (M) months old) with consanguinity of the parents were admitted with relapsing episodes of pain and ‘pseudoparalysis’ of upper and lower extremities since the age of 3 and 6 months, respectively. No concomitant fever has occurred during the attacks. Whole body MRI of the elder brother (M) revealed osteomyelitic changes of the metaphyses of tibiae, left fibula and left radius. Biopsy from lesions showed no malignancy and negative bacterial cultures. Both showed significant hypersedimentation (ESR 92 mm/hr (Y) and 96 mm/hr (M)), slight thrombocytosis, and moderate anemia (Hb 9.0 (Y) and 9.7 (M) g/dl). Bone marrow aspiration was consistent with congenital dyserythropoietic anemia (CDA) with 6% - 9% bi- or multinucleated erythrocytes. LPIN2 gene re-sequencing of each affected child revealed a homozygous 2 bp deletion (c.1312_1313delCT) resulting in an early truncation of the protein (L438fs+16X), which confirmed the diagnosis in both patients. Clinically, both were refractory to the treatment with corticosteroids and TNFα inhibition (etanercept). Elevated plasma levels of proinflammatory cytokines (IL-1β, IL-6, IL-8, TNFα) did not change significantly during the treatment. In M, rapid clinical and laboratory improvement was observed after introduction with anakinra (1.7 mg/kg/d), which has not yet been introduced to Y.

Conclusion

We describe a novel mutation of the LPIN2 gene in two Turkish brothers with Majeed syndrome. Although our patients also presented with CDA none of them had fever during the attacks nor dermatological changes unlike previously described patients with Majeed. IL-1 inhibition showed promising clinical and laboratory results.

Author information

Correspondence to T Herlin.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Herlin, T., Bjerre, M., Fiirgaard, B. et al. Novel mutation of the LPIN2 gene in Turkish brothers with Majeed syndrome. Response to IL-1 inhibition. Pediatr Rheumatol 9, P300 (2011) doi:10.1186/1546-0096-9-S1-P300

Download citation

Keywords

  • Etanercept
  • Thrombocytosis
  • Anakinra
  • Chronic Recurrent Multifocal Osteomyelitis
  • Moderate Anemia